Phase-I trial of HSPCAR30 therapy shows 100% response and 50% remission in CD30+ lymphoma patients with no major side effects ...

Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospital and the Josep ...

A new Brazilian-developed CAR-T cell therapy has shown extraordinary results in treating refractory CD30+ lymphoma, including ...

In a Phase 1 clinical trial, a CAR T-cell therapy targeting the CD30 protein has been shown to promote the expansion of ...

A teenager who was diagnosed with Hodgkin lymphoma has revealed the eight symptoms she suffered prior to her diagnosis.

The EMA has recommended extensions to the marketing authorizations for Adcetris, used to treat Hodgkin lymphoma, and ...

In a significant advancement in cancer treatment, a team of Brazilian researchers has engineered a groundbreaking CAR-T cell ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the CD30-directed antibody-drug conjugate (ADC ...

A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete remission rate, in ...

Hodgkin lymphoma and other CD30+ lymphomas have posed a significant challenge to the medical community, particularly in refractory or relapsed cases where conventional treatments have so far shown ...